Application of Baricitinib in Dermatology

Baricitinib, a first-generation JAK1/2 inhibitor, has been approved for treating rheumatoid arthritis but is now being explored for its potential in treating various dermatological conditions such as atopic dermatitis, psoriasis, vitiligo, and alopecia areata. Recent studies, including clinical trials and case reports from the past five years, have shown promising results, particularly in the treatment of alopecia areata. The review discusses the application, efficacy, side effects, precautions, and limitations of baricitinib in these skin diseases, with a detailed examination of its mechanism in alopecia areata, suggesting it as a new treatment option for skin conditions unresponsive to conventional drugs.